Preventive medicine

Weight changes and heart-related health risks in US adults with overweight or obesity

Updated

Abstract

Among 882,712 individuals with BMI ≥25 kg/m, 52% maintained stable weight over 2 years.

  • Only 1.3% of participants used weight loss medications during this period.
  • Weight loss of 10% was linked to a small but significant reduction in systolic blood pressure by -2.69 mmHg.
  • Diastolic blood pressure decreased by -1.26 mmHg with the same level of weight loss.
  • Low-density lipoprotein cholesterol dropped by -2.60 mg/dL following a 10% weight loss.
  • Glycated hemoglobin levels decreased by -0.27% with the same weight loss, but these benefits were not maintained in the following year.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Declaration of Competing Interest NJP: Research grants from: Amgen, Inc.; AstraZeneca; Boehringer Ingelheim; Duke Clinical Research Institute; Eli Lilly & Company; Novartis Pharmaceuticals, Novo Nordisk Pharmaceutical Company; Verily Sciences Research Company. Consulting fees from AstraZeneca; Boehringer Ingelheim; CRISPR Therapeutics; Eli Lilly & Company, Merck, Novo Nordisk Pharmaceutical Company, Novartis. HM: none. KC: none. ZL: none. WSJ: Research Grants from Boehringer Ingelheim, Bristol-Myers Squibb, Doris Duke Charitable Foundation, Merck, National Institutes of Health, Patient-Centered Outcomes Research Institute; Honoraria/Advisory Committees from Bayer, Bristol-Myers Squibb, Janssen Pharmaceuticals. SM: Consultant for Novo Nordisk, Rhythm pharmaceuticals. Site principal investigator for clinical trials from Novo Nordisk, Eli Lilly, Boehringer Ingelheim. RW: none. MMC: none. FW: Employee of sponsor (Novo Nordisk). NK: Employee at Janssen Pharmaceuticals, Inc. AR: Employee of sponsor (Novo Nordisk), shareholder of stock in sponsor. GS: Employee of sponsor (Novo Nordisk), shareholder of stock in sponsor. EDP: Research support from Amgen, Janssen, BMS, Esperion; Consulting for Janssen, Boehringer Ingelheim, and Cerner. EO: none.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free